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both IAIs and UTIs. As in previous years, amikacin (96.3%-100% 
susceptibility), ertapenem (84.2%-100%) and imipenem (70.3%-
100%) were the most active antimicrobials tested among 
Enterobacterales species. The activity of amoxicillin-clavulanic, 
piperacillin-tazobactam, and ciprofloxacin susceptibility 
was lower, particularly among ESBL-producers. Ertapenem 
susceptibility (88.9%-100%) was retained in ESBL-E. coli isolates 
that were resistant to these antimicrobials but decreased 
(28.6%-100%) in similar isolates of K. pneumoniae. 
Conclusions. Continuous antimicrobial resistance 
surveillance from the SMART study reveals overall maintenance 
of ESBL-producers in Spain, although with higher presence in 
isolates from UTIs than from IAIs. Moreover, ertapenem activity 
was high in E. coli irrespective of ESBL production but decreased 
in K. pneumoniae, particularly among ESBL-producers. 
Key words: antimicrobial resistance surveillance, intra-abdominal 
infection, urinary tract infection, extended-spectrum-beta-lactamases, 
carbapenems
Seguimiento de la sensibilidad antimicrobiana 
de microorganismos gramnegativos procedentes 
de infecciones intraabdominales y urinarias del 
estudio SMART (España, 2016 y 2017)
RESUMEN
Introducción. Las autoridades de Salud Pública re-
ABSTRACT
Introduction. Continuous antimicrobial resistance sur-
veillance is recommended by Public Health authorities. We up-
dated data from the SMART (Study for Monitoring Antimicro-
bial Resistance Trends) surveillance study in Spain.
Material and methods. The antimicrobial susceptibility 
data and extended-spectrum beta-lactamase (ESBL) produc-
tion in isolates recovered from intra-abdominal (IAI) (n=1,429) 
and urinary tract (UTI) (n=937) infections during the 2016-
2017 SMART study in 10 Spanish hospitals were analysed. 
Results. Escherichia coli was the most frequently 
microorganism isolated (48.3% and 53.7%) followed by Klebsiella 
spp. (11.5% and 21.9%) in IAIs and UTIs, respectively. Figures for 
Pseudomonas aeruginosa were 9.0% and 6.1%, being more 
frequently recovered from patients with nosocomial infections. 
Overall, 9.9% (IAI) and 14.0% (UTI) of E. coli, Klebsiella spp. and 
Proteus mirabilis isolates were ESBL-producers, being Klebsiella 
pneumoniae (34.5%) from UTI of nosocomial origin the most 
frequent. ESBL-producers were higher in patients >60 years in 
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enzymes that inactivate them, continue to increase worldwide 
[6]. In addition, the production of ESBL combined with 
mutations affecting permeability can also contribute to the 
carbapenems resistance. This situation warns the need for 
surveillance of susceptibility to antimicrobials, especially to 
carbapenems. Global surveillance programs such as SMART 
(Study for Monitoring Antimicrobial Resistance Trends) 
that evaluates antimicrobial susceptibility to beta-lactam 
antibiotics, including carbapenems, and also aminoglycosides 
and quinolones, against a large number of Gram-negative 
bacilli species collected from IAI and UTI fulfills this function.
In this study, we analysed the antimicrobial susceptibility 
data from isolates recovered in 2016 and 2017 in Spain 
from abdominal samples in patients with diagnosis of IAI 
and urinary samples from patients with UTI included in the 
SMART database. The ESBL production of these isolates is also 
presented. 
MATERIAL AND METHODS
Microorganisms and participating sites. All isolates 
studied were obtained from abdominal samples from patients 
with diagnosis of IAI and from urinary samples from patients 
with UTI. Details on sampling and criteria for the inclusion of 
microorganisms were previously described [7]. During the 2 
years of the study (2016 and 2017) a total of 10 Spanish hos-
pitals participated (H. Universitario Gregorio Marañón, Madrid, 
H. Clínico San Carlos, Madrid, H. Universitario Virgen Macare-
na, Sevilla, H. Universitario Virgen del Rocío, Sevilla, H. Univer-
sitario Marqués de Valdecilla, Santander, H. Universitario Son 
Espases, Palma de Mallorca, H. Clínico Universitario Lozano 
Blesa, Zaragoza, H. Universitario Bellvitge, Hospitalet de Llo-
bregat, Barcelona, H. Universitario y Politécnico La Fe, Valencia, 
and H. Universitario Ramón y Cajal, Madrid). 
 A total of 1,429 intra-abdominal isolates were collected; 
the most frequent were recovered from peritoneal fluid (41%), 
intra-abdominal abscesses (31%) and gall bladder (18%), and 
to a lesser extent and in decreasing order, from the liver, ap-
pendix, pancreas, colon, rectum, and other sources. Most of 
the isolates were obtained during surgery procedures and 
others from paracentesis and percutaneous aspiration of in-
tra-abdominal abscesses. Regarding UTI, a total of 937 isolates 
were obtained, being virtually all urine samples (98%). Isolates 
from other locations (i.e. blood, abdominal drainages, superfi-
cial wounds or perirectal abscesses) were excluded.
The identification of the isolates was performed at 
each hospital and sent to a central laboratory (International 
Health Management Associates, SA. Schaumburg, IL, US) to 
confirm the identification and to establish the susceptibility 
to different antimicrobials of choice for the treatment of IAIs 
or UTIs. All results were included in a centralized database. 
In addition to the source of the sample, patient’s age was 
considered. Following the standard criteria of the Centers for 
Disease Control and Prevention (CDC) the organisms were also 
rated as isolates obtained within 48 h after hospitalization 
comiendan la vigilancia continua de la resistencia a los anti-
microbianos. Se actualizan los datos del estudio SMART (Study 
for Monitoring Antimicrobial Resistance Trends) en España.
Material y métodos. Se analizaron los datos de sensi-
bilidad antimicrobiana y la producción de betalactamasas de 
espectro extendido (BLEE) en aislamientos obtenidos en el es-
tudio SMART de infecciones intraabdominales (IIA) (n=1.429) 
y del tracto urinario (ITU) (n=937) durante 2016-2017 en 10 
hospitales españoles. 
Resultados. Escherichia coli fue el microorganismo más 
frecuente (54,5% y 57,5%, respectivamente), seguido de Kleb-
siella spp. (18,4% y 25,4%) en IIA y en ITU. En Pseudomonas 
aeruginosa estas cifras fueron 9% y 6%, siendo más frecuente 
en la infección nosocomial. El 9,9% (IIA) y el 14% (ITU) del to-
tal de los aislados de E. coli, Klebsiella spp. y Proteus mirabilis 
producían BLEE, obteniéndose la tasa más alta en Klebsiella 
pneumoniae (34.5%) en ITU nosocomial. El mayor porcentaje 
de aislados con BLEE se observó en pacientes >60 años, tanto 
en IIA como en ITU. Como en años anteriores, amikacina (sen-
sibilidad 96,3%-100%), ertapenem (84,2%-100%) e imipenem 
(70,3%-100%) fueron los antimicrobianos más activos en En-
terobacterales. La sensibilidad a amoxicilina-ácido clavulánico, 
piperacilina-tazobactam y ciprofloxacino fue menor, en par-
ticular en los productores de BLEE. La sensibilidad a ertapen-
em (88,9%-100%) se mantuvo en E. coli con BLEE resistente a 
estos antimicrobianos, pero disminuyó (28,6%-100%) en aisla-
dos similares de K. pneumoniae.
Conclusiones. La vigilancia continua de la resistencia a 
los antimicrobianos en el estudio SMART revela el manten-
imiento de la frecuencia de aislados productores de BLEE en 
España, pero con mayor presencia en las ITUs que en las IIAs. 
Además, la sensibilidad a ertapenem fue alta en E. coli con in-
dependencia de la producción de BLEE, pero disminuyó en K. 
pneumoniae, sobre todo en los productores de BLEE.
Palabras clave: vigilancia epidemiológica de la resistencia, infección 
intraabdominal, infección urinaria, betalactamasas de espectro extendido, 
carbapenems
INTRODUCTION
The increase in antimicrobial resistance is a worldwide 
reality that threatens the prevention and effective treatment 
of an increasing number of infections, challenging clinical 
microbiologists and infectious disease specialists [1]. Two of 
the most common infections are urinary tract (UTI) and intra-
abdominal (IAI) infections caused mainly by Enterobacterales, 
in particular Escherichia coli and Klebsiella species [2,3]. In the 
1980s, extended spectrum beta-lactamase (ESBL)-producing 
Enterobacterales were considered one of the leading causes of 
nosocomial infections and later also of those acquired in the 
community [4]. These enzymes have the ability to hydrolyze 
beta-lactam antibiotics, including penicillins, cephalosporins 
and the monobactam aztreonam but not carbapenems [5]. As a 
consequence, carbapenems were considered the antimicrobials 
of choice for the treatment of infections caused by ESBL 
producers, however the prevalence of carbapenemases, 
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Tables 1 and 2 also show the distribution of the most fre-
quent microorganisms according with their origin. The per-
centage of E. coli of isolates in IAI (table 1) acquired in the 
community (54.6%) was higher than in those of nosocomial 
origin (43.4%) (P<0.01). On the contrary, the percentage in P. 
aeruginosa was higher in infections acquired in the hospital 
(9.2% vs. 8.7%) but without statistical significance (P=0.751). 
The same situation occurs, even to a greater extent, in the UTIs 
(community-acquired infection) and 
isolates obtained after 48 h of hospital stay 
(nosocomial infection) [8]. 
Antimicrobial susceptibility and ESBL 
production. Antimicrobial susceptibility 
testing results were obtained at a central 
laboratory (International Health Management 
Associates) using the standard ISO broth 
microdilution method [9]. MIC results were 
interpreted each year according to the most 
recent EUCAST guidelines (http://www.
eucast.org/clinical_breakpoints/). Dried 
MicroScan (Beckman, West Sacramento, 
CA, US) microdilution panels were used. 
The antimicrobials analyzed in this study 
were: piperacillin-tazobactam, cefotaxime, 
ceftazidime, cefepime, imipenem, ertapenem, 
amikacin and ciprofloxacin. In addition, 
susceptibility to amoxicillinclavulanate was 
measured with a MIC gradient test (Etest®, 
bioMérieux, Lyon, France). The quality controls 
strains used were Escherichia coli ATCC 25922, 
E. coli ATCC 35218, Klebsiella pneumoniae 
ATCC 700603 (positive ESBL control) and P. 
aeruginosa ATCC 27853. E. coli, Klebsiella spp. 
and Proteus mirabilis isolates were classified 
as ESBL following CLSI criteria [10]. 
Statistical analysis. The frequency 
comparison (incidence between hospital and 
community isolates) was performed using 
the chi-squared test (χ2) taking P<0.05 as 
statistically significant.
RESULTS
During 2016 and 2017, a total of 1,429 
isolates from IAI and 937 isolates from UTI 
recovered in the 10 Spanish hospitals were 
included (tables 1 and 2). In IAI, the Entero-
bacterales (1,265) constituted 85.5% of the 
total isolates. This figure was 876 isolates 
(93.4%) in UTI. Overall, E. coli was the most 
frequently isolated microorganism (48.3% 
and 53.7%), followed by Klebsiella spp. 
(11.5% and 21.8%) in IAIs and UTIs, respec-
tively. Figures for Pseudomonas aeruginosa 
were 9.0% and 6.1%, being more frequently 
recovered in patients with nosocomial infections. When the 
origin of the isolates was considered (tables 1 and 2), 43.2% 
of IAI isolates were considered to be acquired in the communi-
ty compared to 56.8% that had their origin in the nosocomial 
setting. In UTI, there was also a lower number of isolates from 
community (47.8%) than from nosocomial origin (52.2%). In 
1.5% of IAI isolates, their origin was not specified in the data 
collection sheets. 
Organisms
Community associated Nosocomial associated
No. isolates No. % No. %
Escherichia coli 690 337 54.6 353 43.4
Klebsiella pneumoniae 165 54 8.7 111 13.6
Klebsiella oxytoca 69 39 6.3 30 3.6
Proteus mirabilis 46 17 2.7 29 3.5
Enterobacter cloacae 75 30 4.8 45 5.5
Citrobacter freundii 31 19 3.0 12 1.4
Morganella morganii 27 6 0.9 21 2.5
Serratia marcescens 25 9 1.4 16 1.9
Other Enterobacterales 137 44 7.1 93 11.4
Pseudomonas aeruginosa 129 54 8.7 75 9.2
Other Gram-negative bacilli 35 8 1.2 27 3.3
TOTAL 1,429 617 43.2 812 56.8
Table 1  Distribution of the most common Gram-negative organisms 
collected in intra-abdominal infections in Spain in the 
SMART Study (2016-2017).
Organisms
Community associataed Nosocomial associated
No. isolates No. % No. %
Escherichia coli 504 284 63.3 220 44.9
Klebsiella pneumoniae 205 66 14.7 139 28.4
Klebsiella oxytoca 18 9 2.0 9 1.8
Proteus mirabilis 61 31 6.9 30 6.1
Enterobacter cloacae 16 5 1.1 11 2.2
Citrobacter freundii 11 6 1.3 5 1.0
Morganella morganii 21 8 1.7 13 2.6
Serratia marcescens 7 3 0.6 4 0.8
Other Enterobacterales 33 13 2.9 20 4.0
Pseudomonas aeruginosa 57 22 4.9 35 7.1
Other Gram-negative bacilli 4 1 0.2 3 0.6
TOTAL 937 448 47.8 489 52.2
Table 2  Distribution of the most common Gram-negative organisms 
collected in urinary tract infections in Spain in the SMART 
Study (2016-2017).
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The highest frequency was found in K. pneumoniae 
(25.4%), followed by E. coli (7.6%) and K. oxytoca 
(1.4%). In P. mirabilis none was found. In UTI the 
same pattern was followed with higher percentag-
es: K. pneumoniae had a higher percentage of ESBL 
(32.6%) followed by E. coli (8.1%), K. oxytoca (5.5%) 
and P. mirabilis (1.6%). In all microorganisms with 
ESBL, the frequency of these enzymes was higher 
in nosocomially acquired than in community in-
fections (figure 1), with the exception of E. coli and 
P. mirabilis in IAI. Likewise, an increase of the ESBL 
isolates was observed in parallel with the increase 
of the age of the patients, reaching a frequency 
higher than 8% in those over 60 years in both types 
of infection (figure 2). 
The susceptibility profile for the antibiotics 
studied of the most common microorganisms is 
detailed in table 3. In IAI, the most active antibiot-
ics in Enterobacterales were amikacin (susceptibil-
ity rates range: 96.3%-100%), ertapenem (84.2%-
100%) and imipenem (70.3%-100%). Ciprofloxacin 
demonstrated less activity with a percentage of 
resistance in E. coli greater than 25% and close 
to 40% in K. pneumoniae. Regarding the associa-
tions of penicillins with beta-lactamase inhibitors, 
piperacillin-tazobactam susceptibility ranged from 
66.6% to 100% and amoxicillin-clavulanic acid 
from 58.3% to 81.5% (table 3). In P. aeruginosa, 
amikacin, imipenem and ceftazidime, were the most 
active compounds (96.9%, 76.7% and 72.8% sus-
ceptible, respectively).
In UTI the most active antibiotics against En-
terobacterales were the same as in IAI, with similar 
figures for amikacin (97%-100% susceptibility) and 
higher ones for ertapenem (94.7%-100%) and imi-
penem (90.4%-100%). Regarding ciprofloxacin, the 
loss of activity against isolates from urine is note-
worthy: only 63% of E. coli, 57% of K. pneumoniae 
and 54.1% of P. mirabilis were susceptible to this 
fluoroquinolone. 
On the other hand, considering the most 
frequent microorganisms recovered from IAI 
(n=1,429), 43.2% were of community origin compared to 
56.8% of hospital origin. Of those responsible for the UTIs 
(n=937), 47.8% were community acquired and 52.2% were of 
hospital origin. Tables 4 and 5 comparatively analyze the activ-
ity of the different antibiotics against community and hospital 
isolates. Systematically, in the isolates with higher numbers (E. 
coli and K. pneumoniae), the activity of all antimicrobials was 
higher in those originated in the community. However, in the 
remaining species, there were some exceptions. In those from 
IAI (table 4), the opposite occurs in C. freundii with piperacil-
lin-tazobactam and the third-generation cephalosporins and 
in M. morganii with ciprofloxacin. In UTI (table 5), exceptions 
occurred with amoxicillin-clavulanate and K. pneumoniae, 
with the third-generation cephalosporins and P. mirabilis, C. 
(Table 2). In E. coli, the corresponding numbers are 63.3% in 
the community and 44.9% in nosocomial infection (p<0.01). In 
P. aeruginosa these percentages were 4.9 and 7.1, respectively 
(P=0.150). 
Overall, the Enterobacterales with AmpC-type inducible 
chromosomal β-lactamases, such as Enterobacter cloacae, 
Morganella morganii and Serratia marcescens, were mainly 
recovered in infections of hospital origin, both in IAI and in UTI 
(tables 1 and 2).
The presence of ESBL in Enterobacterales such as E. coli, 
Klebsiella spp. and Proteus mirabilis was specifically studied in 
IAI and in UTI. In IAI a total of 96 (9.9%) were ESBL producers. 
Figure 1  Percentage of Escherichia coli and Klebsiella 
pneumoniae isolates with extended spectrum 
β-lactamases by origin of acquisition of infection in 
the SMART study in Spain comparing intra-abdominal 
(IAI) and urinary tract infections (UTI) infections.
Figure 2  Frequency of Enterobacterales (Escherichia coli, 
Klebsiella pneumoniae, Klebsiella oxytoca and Proteus 
mirabilis) with extended spectrum β-lactamases 
according to age of the patients in the SMART study 
in Spain comparing intra-abdominal (IAI) and urinary 
tract infections (UTI) infections.
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niae, ertapenem activity was retained to a lesser extent. In IAI, 
28.6% of ESBL producers that were also resistant to amoxi-
cillin-clavulanate were susceptible to ertapenem and in UTI 
38.9% of ESBL producers that were resistant to piperacillin-ta-
zobactam were susceptible to ertapenem.
DISCUSSION
Antimicrobial resistance is a global increased problem and 
poses challenges for the effective treatment of many types of 
infections, including IAI and UTI. This situation, mainly due to 
its wide dispersion, is especially alarming in relation to micro-
organisms that produce ESBL. As a consequence, carbapenems 
are generally considered the treatment of choice for these in-
fections [11,12], although a decrease in the susceptibility to 
these compounds have been observed due to the production 
of carbapenemases or alterations in the porins combined with 
the production of ESBL or AmpC cephalosporinases [13,14]. Ep-
idemiological surveillance studies analyze trends in resistance 
but also allow data to progressively adapt treatment guidelines 
over time, providing valuable information for the selection of 
initial antibiotic treatment, often empirical. The SMART study 
(Study for Antimicrobial Resistance Trends), initiated in 2002, 
is a worldwide program designed to longitudinally monitor the 
involvement of aerobic and facultative Gram-negative bacilli 
in IAI, both from community and nosocomial acquisition, as 
well as their patterns of resistance [15-18]. As of 2009, micro-
organisms isolated from UTI were also included. The program 
has been developed in Spain uninterruptedly since 2002 and 
has had the participation of a significant number of Micro-
biology Departments of Spanish University Hospitals. Previous 
freundii and M. morganii, with ciprofloxacin in P. mirabilis and 
M. morganii and with imipenem in S. marcescens. Moreover, 
in P. aeruginosa recovered from IAI, all the antibiotics tested 
were more active when this pathogen was originated in the 
community, but in the UTI this premise was not observed with 
piperacillin-tazobactam, ceftazidime and cefepime.
When ESBL producers were considered and compared 
with non-ESBL producers in IAI (figure 3), the activity of im-
ipenem (99.6% non-ESBL, 100% ESBL) and ertapenem (99.3% 
non-ESBL, 100% ESBL) remained about at the same level in E. 
coli whereas amikacin was slightly affected (98.9% non ESBL, 
86.7% ESBL). On the contrary, the associations of penicillins 
with the beta-lactamase inhibitors, as well as third genera-
tion cephalosporins and ciprofloxacin importantly decreased 
their activity. In K. pneumoniae, amikacin susceptibility (100% 
non-ESBL, 95.2% ESBL) was little affected compared with that 
of imipenem (97.5% non-ESBL, 88.1% ESBL) and especially 
with ertapenem (97.5% non ESBL, 45.2% ESBL) and decreases 
drastically in the rest of antibiotics as described in E. coli. In 
UTI, E. coli isolates showed similar results than those described 
for IAI. In K. pneumoniae, the activity of ertapenem was af-
fected (96.3% non ESBL, 67.1% ESBL), although to a lesser ex-
tent than in the IAI isolates.  
Finally, when analyzing the activity of carbapenems both 
in ESBL and in non-ESBL producing E. coli and K. pneumoniae 
that were resistant to amoxicillin-clavulate, piperacillin-ta-
zobactam or ciprofloxacin from IAI and UTI (table 6), it was 
observed that in E. coli both the activity of imipenem (data 
not shown) and that of ertapenem was scarcely modified with 
susceptibility values  higher than 88%. However, in K. pneumo-
Organism
Percentage of susceptible isolatesa
A/Ca P/T CTX CAZ FEP IPM ETP AK CIP
Type of infection IAI UTI IAI UTI IAI UTI IAI UTI IAI UTI IAI UTI IAI UTI IAI UTI IAI UTI
Escherichia coli 81.5 77.7 90.0 90.9 90.5 90.1 89.8 89.1 92.0 90.9 99.7 99.8 99.4 99.4 97.9 99.0 72.4 63.0
Klebsiella pneumoniae 58.3 94.1 66.6 69.7 72.7 64.3 67.8 64.8 72.7 65.3 95.1 97.0 84.2 86.8 98.7 97.0 62.4 57.0
Klebsiella oxytoca 76.3 100.0 85.5 84.2 97.1 94.7 97.1 94.7 100.0 94.7 100.0 100.0 100.0 94.7 100.0 100.0 97.1 89.4
Proteus mirabilis 74.1 100.0 100.0 100.0 100,0 96.7 100.0 93.4 100.0 100.0 91.3 100.0 100.0 100.0 100.0 100.0 60.8 54.1
Enterobacter cloacae _b _b 78.6 58.8 73.3 52.9 72.0 58.8 84.0 82.3 96.0 94.1 85.3 94.1 97.3 100.0 90.6 70.5
Citrobacter freundii _b _b 70.9 90.9 70.9 72.7 54.8 63.6 87.1 90.9 93.5 90.9 96.7 90.9 100.0 100.0 93.5 81.8
Morganella morganii _b _b 100,0 95.2 51.8 71.4 74.0 66.6 96.3 95.2 70.3 90.4 100.0 100.0 96.3 100.0 70.3 66.6
Serratia marcescens _b _b 88,0 100,0 72.0 100.0 96.0 100.0 92.0 100.0 92.0 100.0 92.0 100.0 100.0 100.0 96.0 85.7
Other Enterobacterales 36.3 60.0 79.8 74.1 82.4 84.8 72.8 78.7 98.2 93.9 99.1 100.0 96.4 100.0 98.2 100.0 91.2 87.8
Pseudomonas aeruginosa _b _b 66.6 81.8 _b _b 72.8 77.5 72.0 74.1 76.7 81.0 _b _b 96.9 91.3 70.5 67.2
Table 3  Activity of different antimicrobial used in intra-abdominal (IAI) and urinary tract infections (UTI) 
against the most common microorganisms collected in Spain in the SMART study (2016-2017).
aEUCAST criteria except A/C in which CLSI criteria were considered.  A/C: amoxicillin-clavulanic acid, P/T: piperacillin/tazobactam; CTX: cefotaxime; CAZ: ceftazidime; FEP: 
cefepime; IPM: imipenem; ETP: ertapenem; AK: amikacin; CIP: ciprofloxacin
bThis antimicrobial is not considered adequate against the microorganism tested.
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We confirm the relevance of E. coli in IAI and UTI and 
in both cases it is isolated in greater proportion in commu-
nity-acquired infections than in nosocomial infections, in line 
with other recent publications [20-22]. K. pneumoniae is the 
second microorganism in order of frequency in both types of 
infections and unlike the previous period (2011-2015) a great-
er proportion of isolates was found in nosocomial compared to 
community infections, both in IAI and in UTI.
articles represent the general picture of antimicrobial suscep-
tibility in our country; the last one (7) updates up to 2015 the 
evolution of ESBL producing isolates in IAIs in Spain. In the 
present study, the following two years (2016 and 2017) were 
analyzed but also including information from UTI pathogens. 
In general, the results are in line with those obtained in the 
2011-2015 period and with others from different regions of 
the world [13,19-21]. 
Organism
Percentage of susceptible isolatesa
A/Ca P/T CTX CAZ FEP IPM ETP AK CIP
Type of infection CA HA CA HA CA HA CA HA CA HA CA HA CA HA CA HA CA HA
Escherichia coli 88.7 75.9 93.4 86.6 91.3 89.8 91.0 88.6 91.6 92.3 100,0 99.3 99.4 99.4 98.5 97.4 75.3 69.9
Klebsiella pneumoniae 83.8 48.7 85.4 57.6 87.2 65.7 85.4 59.4 87.2 65.7 100.0 92.7 96.3 78.3 100.0 98.2 74.5 55.8
Klebsiella oxytoca 84.2 68.4 92.3 76.6 97.4 96.6 97.4 96.6 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 97.4 96.6
Proteus mirabilis 62.5 78.2 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 94.1 89.6 100.0 100.0 100.0 100.0 64.7 58.6
Enterobacter cloacae _b _b 93.3 68.8 83.3 66.6 80.0 66.6 90.0 80.0 100.0 93.3 93.3 80.0 100.0 95.5 96.6 86.6
Citrobacter freundii _b _b 68.4 75.0 68.4 75.0 57.8 50.0 89.4 83.3 94.7 91.6 100.0 91.6 100.0 100.0 94.7 91.6
Morganella morganii _b _b 100.0 100.0 66.6 47.6 66.6 76.1 100.0 95.2 83.3 66.6 100.0 100.0 100.0 95.2 50.0 76.1
Serratia marcescens _b _b 88.8 87.5 66.6 75.0 100.0 93.7 100.0 87.5 100.0 87.5 100.0 87.5 100.0 100.0 100.0 93.7
Pseudomonas aeruginosa _b _b 79.6 57.3 _b _b 85.1 64.0 88.8 60.0 88.8 68.0 _b _b 98.1 96.0 79.6 64.0
Table 4  Susceptibility of community-associated (CA) and hospital-associated (HA) microorganisms collected 
of IAI in Spain in the SMART study (2016-2017).
aEUCAST criteria except A/C in which CLSI criteria were considered. A/C: amoxicillin-clavulanic acid, P/T: piperacillin/tazobactam; CTX: cefotaxime; CAZ: ceftazidime; FEP: 
cefepime; IPM: imipenem; ETP: ertapenem; AK: amikacin; CIP: ciprofloxacin
bThis antimicrobial is not considered adequate against the microorganism tested.
Organism
Percentage of susceptible isolatesa
A/Ca P/T CTX CAZ FEP IPM ETP AK CIP
Type of infection CA HA CA HA CA HA CA HA CA HA CA HA CA HA CA HA CA HA
Escherichia coli 77.6 78.2 91.5 90.0 92.6 86.8 91.5 85.9 92.6 88.6 100.0 99.5 99.6 99.0 99.3 98.6 64.0 61.3
Klebsiella pneumoniae 90.0 100.0 71.2 69.0 66.6 63.3 69.7 62.5 69.7 63.3 100.0 95.6 92.4 84.1 98.4 96.4 59.0 56.1
Klebsiella oxytoca 100.0 0.0 88.8 77.7 100.0 88.8 100.0 88.8 100.0 88.8 100.0 100.0 100.0 88.8 100.0 100.0 100.0 77.7
Proteus mirabilis 100.0 100.0 100.0 100.0 93.5 100.0 90.3 96.6 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 51.6 56.6
Enterobacter cloacae _b _b 100.0 36.3 80.0 36.3 100.0 36.3 100.0 72.7 100.0 90.9 100.0 90.9 100.0 100.0 100.0 54.5
Citrobacter freundii _b _b 100.0 80.0 66.6 80.0 50.0 80.0 100.0 80.0 100.0 80.0 100.0 80.0 100.0 100.0 83.3 80.0
Morganella morganii _b _b 100.0 92.3 50.0 84.6 37.5 84.6 100.0 92.3 87.5 92.3 100.0 100.0 100.0 100.0 62.5 69.2
Serratia marcescens _b _b 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 66.6 100.0 100.0 100.0 100.0 100.0 100.0 75.0
Pseudomonas aeruginosa _b _b 72.7 77.1 _b _b 77.2 80.0 72.7 77.1 81.8 80.0 _b _b 95.4 88.5 68.1 68.5
Table 5  Susceptibility of community-associated (CA) and hospital-associated (HA) microorganisms 
collected of UTI in Spain in the SMART study (2016-2017).
aEUCAST criteria except A/C in which CLSI criteria were considered.  A/C: amoxicillin-clavulanic acid, P/T: piperacillin/tazobactam; CTX: cefotaxime; CAZ: ceftazidime; FEP: 
cefepime; IPM: imipenem; ETP: ertapenem; AK: amikacin; CIP: ciprofloxacin
bThis antimicrobial is not considered adequate against the microorganism tested.
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the percentage of susceptibility is 86.8%, slightly lower to that 
published in studies from other countries [3,21]. 
In a recent publication, small decreases, although 
statistically significant, of ertapenem susceptibility 
in Enterobacterales isolated from IAI and UTI were 
observed in most regions of the world. Nevertheless, the 
susceptibility remains above 90% in all regions, except in 
Asia [22]. In community infections, the activity was >92% 
in all regions against Enterobacterales [22] despite the 
existence of communications that alert of the increase in 
resistance [6]. Another recent study, unrelated to SMART, 
Given its epidemiological importance, knowledge of 
the antimicrobial susceptibility of E. coli is crucial regarding 
empirical therapy, as well as for attempts to control the spread 
of ESBL and, more recently, of carbapenemases. As in other 
studies [3,13,19,21], imipenem, ertapenem and amikacin were 
the most active antimicrobials tested against E. coli in both 
IAIs (>97%), and UTIs (>99%) (21) and there is no evidence of 
loss of activity in 2016 and 2017 compared to 2011-2015 [7]. 
On the contrary, in K. pneumoniae a decrease in the activity of 
ertapenem in IAI is verified by comparing the two time periods 
(95.5% in 2011-2015 versus 84.2% in 2016-2017) [7]. In UTI, 
Figure 3  Percentage of susceptibility of different antimicrobials 
used in intra-abdominal (A) and urinary tract infections 
(B) against ESBL producing and non-ESBL-producing 
Escherichia coli and Klebsiella pneumoniae in the SMART 
study in Spain (2016-2017).
A/C: amoxicillin-clavulanic acid, P/T: piperacillin/tazobactam; CTX: cefotaxime; CAZ: ceftazidime; FEP: cefepime; IPM: 
imipenem; ETP: ertapenem; AK: amikacin; CIP: ciprofloxacin
A)
B)
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reported a percentage of susceptibility to ertapenem in 
the Enterobacterales group of 94.5% (98.7% in E. coli and 
87.4% in K. pneumoniae) [23]. In the study of Lob et al. [22], 
susceptibility to ertapenem significantly decreased in K. 
pneumoniae between 2012 and 2016 in Africa (6%), Europe 
(8%) and US/Canada (2.5%). Despite this fact, in 2016 the 
susceptibility of K. pneumoniae to ertapenem remains above 
90% in the US/Canada and in the South Pacific area, being 
greater than 80% in the rest of the world. 
In recent years, there is a continuous increase in the 
rates of Enterobacterales with ESBL around the world, espe-
cially in Asia [24]. In a recent review of the global epidemi-
ology, the prevalence of CTX-M ESBLs increased over time in 
all geographic regions, especially in community isolates [25]. 
In our study, in IAI the percentage of ESBL in E. coli is overall 
7.6% (8.3% in community and 7% in nosocomial infection), 
keeping the total figures in line with the period 2011-2015 
[7]. It is noteworthy that the rate is somewhat higher in 
community-acquired infections, a fact not communicated in 
most of the published surveillance studies [13,21], although 
the reports on the spread of ESBL in the community are wor-
risome [26,27]. In K. pneumoniae, the ESBL rate increased 
with respect to previous years, from 18.6% in 2015 to 25.4% 
in 2016-2017, especially at the expense of infections of no-
socomial origin (12.7% community and 31.5% nosocomial). 
In UTI, the figures in ESBL producing E. coli are slightly higher 
(overall 8.1%; 6.3% community and 10.4% nosocomial) and 
much higher in K. pneumoniae (overall 32.6%; 28.7% com-
munity and 34.5% nosocomial). Our rates of ESBL in K. pneu-
moniae are difficult to compare with those published in other 
regions where there are large variations, although it can be 
summarized that they are lower than those of most countries 
in Asia, especially China and Thailand [3], and higher than 
those of the US/Canada [28]. Our study also shows that the 
highest percentage of ESBL isolates occurs in IAI of hospital 
origin and in patients of advanced ages. Both circumstances 
have already been indicated as risk factors for the acquisition 
of infections due to ESBL producers [29]. In this line, in a re-
cent study in UTI in the US when data are stratified by sex, 
age and time of hospital stay, there is a higher percentage of 
ESBL isolations in men, patients ≥65 years and in nosocomial 
infections [28].
In IAI, the activity of imipenem, ertapenem and amikacin 
in ESBL-producing E. coli isolates remains practically at the 
Table 6  Activity of ertapenem in ESBL producing Escherichia coli and Klebsiella pneumoniae isolates resistant 
to amoxicillin-clavulanate, piperacillin-tazobactam and ciprofloxacin in intra-abdominal (IAI) and 
urinary tract infections (UTI) of the SMART study (2016-2017) in Spain.
A/C: amoxicillin-clavulanate; P/T: piperacillin/tazobactam; CIP: ciprofloxacin 
Microorganisms ESBL Antimicrobial
No.
(% of resistant isolates)
IAI
No.
(% of resistant isolates)
UTI
 Ertapenem  Ertapenem
Susceptible Intermediate Resistant Susceptible Intermediate Resistant
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Escherichia coli Negative 65 (15.8) 64 (98.4) 1 (1.6) 26 (20.8) 26 (100)
A/C
Positive 16 (45.7) 16 (100) 4 (40) 4 (100)
Negative 46 (7.2) 43 (93.4) 1 (2.2) 2 (4.4) 18 (3.8) 17 (94.4) 1 (5.6)
P/T
Positive  10 (18.8) 10 (100)   9 (21.9) 8 (88.9) 1 (11.1)  
Negative 126 (19.7) 123 (97.7) 3 (2.3) 137 (29.4) 136 (99.3) 1 (0.7)
CIP
 Positive  42 (79.2) 42 (100)   39 (95.1) 38 (97.4) 1 (2.6)  
Klebsiella pneumoniae Negative 17 (22) 14 (82.4) 3 (17.6) 1 (3.4) 1 (100)
A/C
Positive 28 (87.5) 8 (28.6) 20 (71.4) 1 (20) 1 (100)
Negative 14 (33.3) 11 (78.6) 3 (21.4) 11 (7.9) 6 (54.5) 5 (45.5)
P/T
Positive  38 (30.6) 16 (42.1)  22 (57.9) 36 (53.7) 14 (38.9) 2 (5.5) 20 (55.6)
Negative 15 (35.7) 13 (86.7) 2 (13.3) 16 (11.5) 12 (75) 4 (25)
CIP
 Positive  40 (32.2) 17 (42.5) 1 (2.5) 22 (55) 61 (91) 40 (65.6) 2 (3.3) 19 (31.1)
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same level in relation to those that do not produce ESBLs. 
This fact is also confirmed in other publications [13,21,22]. 
However, one of these articles [13] found some evidence of 
increased resistance among isolates from the community, 
in addition to the known decreasing trends in susceptibility 
to quinolones and third-generation cephalosporins. In ES-
BL-producing K. pneumoniae, the activity of imipenem de-
creased by almost 10% and that of ertapenem by more than 
50%. This decrease is not reflected so strongly in any other 
study and follows the trend already mentioned in the study 
of the years 2010-2016 in Spain [7]. Ertapenem susceptibili-
ty figures below 90% (83.6% in Africa and 85.5% in Europe) 
have already been published, although data came from a 
joined analysis including E. coli, K. pneumoniae, K. oxytoca 
and P. mirabilis ESBL producers from IAI and UTI and not 
from an individualized analysis [22].
In UTI, the behavior of imipenem, ertapenem and amikacin 
in E coli. and K. pneumoniae is similar to that commented for 
IAI. However, the activity of ertapenem decreased to a lesser 
extent (somewhat less than 30%) in K. pneumoniae being 
higher than in other publications [3,21]. Regarding the origin 
of the isolates, E. coli slightly decreased their susceptibility 
to the most active compounds (imipenem, ertapenem and 
amikacin) when having a hospital origin both in IAI and in UTI, 
in line with what it is reflected in other studies [3,19,21]. In K. 
pneumoniae, in IAI, the susceptibility decreased to a greater 
extent, data not sufficiently confirmed in other studies to date 
[3,19,21]. 
As in the 2011-2015 study the co-resistance analysis, 
which is relevant to designing antimicrobial treatment 
protocols [30], showed that both imipenem (data not shown) 
and ertapenem have a good activity against ESBL-producing 
E. coli recovered from IAI and UTI that were also resistant 
to amoxicillin-clavulanic acid, piperacillin-tazobactam or 
fluoroquinolones. Nevertheless, the same did not occur 
in the case of ESBL-producing K. pneumoniae, although 
ertapenem retained its activity in 28.6%, 42.1% and 42.5% 
of amoxicillin-clavulanic acid, piperacillin-tazobactam or 
ciprofloxacin resistant isolates, respectively. These figures were 
more favorable in UTI, particularly for ciprofloxacin resistant 
isolates (65.6% of ertapenem susceptibility). The reason for the 
increased loss of susceptibility to ertapenem in K. pneumoniae 
was analyzed in a recent study and concluded that it was not 
only due to production of carbapenemases but to permeability 
defects [31]. The genes encoding the OmpK35 and OmpK36 
porins of the outer membrane were studied and most of the 
isolates (83.0%) had one or both genes affected. In isolates 
with higher  ertapenem MICs (>4 mg/L), 60.5% of the total 
isolates, a mutation was found in both porin genes. 
Despite the above observations, carbapenems are still con-
sidered as empirical therapy of choice in infections suspected to 
be caused by ESBL producers or AmpC hyperproducers both in 
IAI and UTI [12,32,33]. Regardless of the spread of ESBL world-
wide, a very recent study showed that ertapenem was active 
against more than 90% of Enterobacterales isolates recovered 
from IAI and UTI with the ESBL phenotype in Latin America, 
Middle East, South Pacific, US and Canada. Our study also shows 
that ertapenem continue to exhibit good activity, despite the 
emergence of carbapenemases in Spain [34,35], when compared 
to broad spectrum cephalosporins and associations of penicillins 
with beta-lactamase inhibitors. This activity is higher in isolates 
from community origin and may be a viable option to reduce 
the length of hospitalization of stable patients together with its 
easy once-a-day dosing, safety and tolerability [36,37]. Continu-
ous surveillance efforts should be performed at local and global 
levels, since knowledge of the patterns and resistance trends are 
essential for making decisions about empirical treatment and 
support infection control efforts.
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